Saturday, July 11, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 588
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

588 results for “placebo” Back to intelligence hub

Search results

Page 10 of 25
  1. Rocatinlimab, Placebo for AMG 451

    Amgen

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial
  2. Sovateltide, Sovateltide matching placebo

    Lacuna Pharma Pty Ltd

    Acute cerebral ischemic stroke

    phase 3 small molecule active

    1 trial
  3. Spesolimab, Placebo matching to Spesolimab

    Boehringer Ingelheim

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial
  4. TOCILIZUMAB, Placebo of Tocilizumab

    Pari Pharma GmbH

    Giant cell arteritis with Cerebro-vascular involvement

    phase 3 small molecule active

    1 trial
  5. Teplizumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Nutritional and metabolic diseases

    phase 3 small molecule active

    1 trial
  6. The placebo product consists of a soft capsul...

    Fondazione Telethon ETS

    Prevention of recurrence after a first episode of Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial
  7. The placebo tablet composition is: Collodial...

    The George Institute

    Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN

    phase 3 small molecule active

    1 trial
  8. Tinlarebant 5 mg´s matching Placebo, LBS-008

    ELITE PHARMACEUTICALS INC /NV/

    Stargardt Disease

    phase 3 small molecule active

    1 trial
  9. Tozorakimab, Tozorakimab-placebo

    AstraZeneca AB

    Severe viral lung infections

    phase 3 small molecule active

    1 trial
  10. UI022 or UI023 and co-administration of matching placebo

    United Therapeutics Europe Ltd

    Peripheral Arterial Disease

    phase 3 small molecule completed

    1 trial
  11. Upadacitinib Placebo, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    non-segmental vitiligo

    phase 3 small molecule active

    1 trial
  12. Vedolizumab Placebo

    Takeda

    Hematopoietic Stem Cells

    phase 3 small molecule completed

    1 trial
  13. XPF-010, Placebo to match XPF-010

    Xenon Pharmaceuticals

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial
  14. a compound glutamine capsule/a compound glutamine capsule simulated placebo

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mucositis

    phase 3 small molecule active

    1 trial
  15. budesonide/formoterol 'as needed' + budesonide placebo bid

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial
  16. elafibranor, Elafibranor Placebo

    Ipsen

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial
  17. elafibranor, Placebo

    Ipsen

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial
  18. elafibranor, Placebo tablet

    Ipsen

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial
  19. matched placebo for test product, Duvakitug

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial
  20. placebo

    Boehringer Ingelheim

    Pulmonary Fibrosis

    phase 3 small molecule completed

    1 trial
  21. placebo

    Takeda

    Osteoporosis

    phase 3 small molecule completed

    1 trial
  22. placebo

    Jazz Pharmaceuticals Ireland Limited

    Fibromyalgia

    phase 3 small molecule completed

    1 trial
  23. placebo

    Takeda

    Non-cancer Pain

    phase 3 small molecule terminated

    1 trial
  24. placebo

    Pfizer

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.